Skip to main content
Advertising

Originally published September 3, 2014 at 2:48 PM | Page modified September 4, 2014 at 6:35 AM

  • Share:
           
  • Comments
  • Print

Google's health startup forges venture with AbbVie

Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.


advertising

SAN FRANCISCO —

Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.

The alliance announced Wednesday calls for Google Inc. and AbbVie Inc. to each invest $250 million in the project. An additional $1 billion may be poured into the project. The two companies will split all expenses and any profits generated by the venture.

Calico, a company hatched by Google last year, will manage a team of scientists who will work at a research-and-development lab in the San Francisco Bay Area. The precise location and size of the new lab hasn't been determined.

AbbVie, a spin-off from Abbott Laboratories, will oversee the marketing of the drugs. The North Chicago, Illinois, company already has been working on drugs to fight Parkinson's disease, Crohn's and other ailments.

Google set up Calico as separate business last year to pursue medical breakthroughs that would enable people to live longer. Toward that end, Calico is doing extensive research to get a better understanding about how the human body ages and working on technology that could cure cancer.

Calico is run by Arthur Levinson, a former CEO of biotech pioneer Genentech and a former member of Google's board. He is also chairman of Apple Inc., which is expected to provide further details to help people manage their health next week when the company unveils its latest iPhone. The expansion into health also could include a new Apple device that could be worn on a person's wrist.

AbbVie Inc. shares slipped 8 cents to $54.99 in afternoon trading Wednesday, while Google shares gained 25 cents to $577.58.



Want unlimited access to seattletimes.com? Subscribe now!

Also in Business & Technology

News where, when and how you want it

Email Icon

Want free career advice? And an iPad Mini?

Want free career advice? And an iPad Mini?

Tell us about your goals and challenges and be considered for a future NWjobs career-makeover story, as well as a chance to win an iPad Mini!

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►